ClinicalTrials.gg
CompletedNCT03916744Updated Mar 10, 2023Results posted

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

A Phase 1 interventional study of Giredestrant and Surgery in Breast Cancer, sponsored by Genentech, Inc.. Completed at 15 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Enrollment
15th of 16
75 · median 302
Started
2019
the only one that year
Phase 1
2 of 16
none open now
Registered
2nd of 16
by date
Lead sponsor
4 of 16
Genentech, Inc.

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 15th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comply with the study protocol, in the investigator's judgment
  • confirmed invasive breast carcinoma, with all of the following characteristics: Primary tumor greater than or equal to (≥)1.5 centimeters (cm) in largest diameter by ultrasound; Stage I-III operable breast cancer; Documentation confirming the absence of distant (M0) as determined by institutional practice.
  • ER-positive tumor and -negative breast cancer as per local laboratory testing
  • status
  • Breast cancer eligible for primary surgery
  • Submission of a representative tumor tissue specimen
  • (ECOG) Performance Status less than or equal to (≤)1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of inflammatory breast cancer
  • Diagnosis of bilateral breast cancer
  • Concurrent use of hormone replacement therapies
  • Previous systemic or local treatment for the primary breast cancer currently under investigation
  • Concurrent treatment with other experimental drugs or participation in another clinical trial with any drug within 30 days prior to study entry
  • Current treatment with any systemic anti-cancer therapies
  • Major surgery within 4 weeks prior to enrollment
  • Radiation therapy within 2 weeks prior to enrollment
  • Diagnosis of any secondary within 3 years prior to enrollment, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
  • Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
  • Known infection
  • Known history of liver disease consistent with Class B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  • History of allergy to giredestrant or any of its
  • Any condition requiring anti-coagulants, such as warfarin, heparin, or thrombolytic drugs
  • History of documented hemorrhagic diathesis or coagulopathy
  • History or presence of symptomatic bradycardia or sick sinus syndrome
  • Baseline heart rate ≤55 beats per minute (bpm) prior to enrollment
  • History or presence of an abnormal (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
  • corrected through use of Fridericia's formula (QTcF) >470 milliseconds demonstrated by at least two ECGs >30 minutes apart
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease, clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome
  • Current treatment with medications that are well known to prolong the QT interval
  • History or presence of uncontrolled hypothyroidism
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Giredestrant 10 mg

    Drug: Giredestrant · Procedure: Surgery

  • Experimental
    Giredestrant 30 mg

    Drug: Giredestrant · Procedure: Surgery

  • Experimental
    Giredestrant 100 mg

    Drug: Giredestrant · Procedure: Surgery

Interventions

  • Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).

    Also known as: GDC-9545, RO7197597, RG6171

  • ProcedureSurgery

    Breast cancer surgery will take place on Day 15 (+/-2 days).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples

    The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the proportion of nuclei staining Ki67-positive (Ki67+) in the tumor biopsy sample taken post-treatment (at surgery) relative to that in the pre-treatment sample (at baseline).

    Time frame: Baseline and Surgery (Day 15)

  2. Change From Baseline in Tumor Cell Proliferation, as Measured by the Difference in the Percentage of Nuclei Staining Ki67-Positive at Surgery Compared With Baseline in Pre- and Post-Treatment Tumor Biopsy Samples

    The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the percentage of nuclei staining Ki67-positive (Ki67+) in the pre- and post-treatment tumor biopsy samples (taken at baseline and surgery, respectively) and the absolute difference in the percentage of Ki67+ nuclei between the two samples (calculated as surgery minus baseline).

    Time frame: Baseline and Surgery (Day 15)

Secondary outcomes

  1. Number of Participants With at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)

    All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. Investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE was considered to be related to the study drug.

    Time frame: From Baseline to Day 43

  2. Percentage of Participants With Abnormal Vital Signs During Treatment

    Vital signs, which included diastolic and systolic blood pressure, pulse rate, and body temperature, were measured while the participant was sitting and according to institutional practices. Any of the vital signs that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). A vital sign result had to be reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Baseline, Days 1, 8, and 15

  3. Change From Baseline in Pulse Rate

    Pulse rate was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

    Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)

  4. Change From Baseline in Systolic Blood Pressure

    Systolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

    Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)

  5. Change From Baseline in Diastolic Blood Pressure

    Diastolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

    Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)

  6. Change From Baseline in Body Temperature

    Body temperature was measured according to institutional practice. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

    Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)

  7. Percentage of Participants With Laboratory Abnormalities in Hematology Tests During Treatment, Among Participants Without the Abnormality at Baseline

    Laboratory parameters for hematology will be measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Baseline, Days 1, 8, and 15

  8. Percentage of Participants With Laboratory Abnormalities in Blood Chemistry and Coagulation Tests During Treatment, Among Participants Without the Abnormality at Baseline

    Laboratory parameters for blood chemistry and coagulation were measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase

    Time frame: Baseline, Days 1, 8, and 15

  9. Percentage of Participants With Abnormal Electrocardiogram Parameters During Treatment

    Electrocardiogram (ECG) recordings were performed after the participant had been resting in a supine position for at least 10 minutes. ECG parameters included heart rate, PR and QRS durations, and QT and QTcF intervals. Per the protocol, ECG readings post-treatment were limited to those for whom it was clinically indicated. Any of the ECG parameters that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). An ECG test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Baseline, Days 1, 8, and 15

  10. Plasma Concentration of Giredestrant at Steady State by Dose Level

    Plasma samples were obtained on the day of surgery (Day 15), or prior to biopsy on Day 14.

    Time frame: Predose on day of surgery (Day 15), or prior to biopsy (Day 14)

07

Results

Posted Mar 10, 2023

Participant flow

Participant flow — Overall Study
MilestoneGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mg
Started174018
Received at least one dose of study drug174017
Completed173916
Not completed012
Withdrew: Withdrawal by subject012

Outcome measures

PrimaryChange From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples

The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the proportion of nuclei staining Ki67-positive (Ki67+) in the tumor biopsy sample taken post-treatment (at surgery) relative to that in the pre-treatment sample (at baseline).

Time frame:
Baseline and Surgery (Day 15)
Reported as:
Geometric mean · Proportion of Ki67+ nuclei
Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples
Proportion of Ki67+ nucleiGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Efficacy: Giredestrant (10, 30, or 100 mg)
Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples0.20 (0.12 to 0.31)0.24 (0.18 to 0.32)0.22 (0.13 to 0.37)0.22 (0.18 to 0.28)
PrimaryChange From Baseline in Tumor Cell Proliferation, as Measured by the Difference in the Percentage of Nuclei Staining Ki67-Positive at Surgery Compared With Baseline in Pre- and Post-Treatment Tumor Biopsy Samples

The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the percentage of nuclei staining Ki67-positive (Ki67+) in the pre- and post-treatment tumor biopsy samples (taken at baseline and surgery, respectively) and the absolute difference in the percentage of Ki67+ nuclei between the two samples (calculated as surgery minus baseline).

Time frame:
Baseline and Surgery (Day 15)
Reported as:
Mean · Percentage of nuclei Ki67+
Change From Baseline in Tumor Cell Proliferation, as Measured by the Difference in the Percentage of Nuclei Staining Ki67-Positive at Surgery Compared With Baseline in Pre- and Post-Treatment Tumor Biopsy Samples
Percentage of nuclei Ki67+Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Efficacy: Giredestrant (10, 30, or 100 mg)
Baseline (BL) - Value at Visit15.70 ± 9.2515.10 ± 11.2315.58 ± 9.9515.35 ± 10.36
Surgery - Value at Visit4.22 ± 4.704.12 ± 4.354.08 ± 3.804.13 ± 4.25
Change from BL at Surgery (Surgery minus BL)-11.49 ± 7.84-10.98 ± 8.53-11.49 ± 8.23-11.21 ± 8.18
SecondaryNumber of Participants With at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)

All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. Investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE was considered to be related to the study drug.

Time frame:
From Baseline to Day 43
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)
ParticipantsGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Any Adverse Event (AE)12271453
AE with Fatal Outcome0000
Serious AE1214
Related Serious AE0000
AE Leading to Withdrawal from Study Drug0000
AE Leading to Interruption of Study Drug1012
Related AE717832
Grade 3-4 AE1315
Related Grade 3-4 AE0000
SecondaryPercentage of Participants With Abnormal Vital Signs During Treatment

Vital signs, which included diastolic and systolic blood pressure, pulse rate, and body temperature, were measured while the participant was sitting and according to institutional practices. Any of the vital signs that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). A vital sign result had to be reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Baseline, Days 1, 8, and 15
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormal Vital Signs During Treatment
Percentage of participantsGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Diastolic Blood Pressure - Low5.912.523.513.5
Diastolic Blood Pressure - High64.735.011.836.5
Systolic Blood Pressure - High82.470.058.870.3
Pulse Rate - Low11.827.564.732.4
Pulse Rate - High02.501.4
Body Temperature - Low88.282.594.186.5
SecondaryChange From Baseline in Pulse Rate

Pulse rate was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

Time frame:
Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate
beats per minuteGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Baseline (BL) - Value at Visit75.3 ± 9.572.6 ± 11.172.1 ± 10.673.1 ± 10.6
Change from BL at Day 81.4 ± 8.5-1.9 ± 11.3-11.1 ± 10.6-3.1 ± 11.3
Change from BL at Surgery2.4 ± 9.7-3.8 ± 10.7-13.9 ± 10.8-4.5 ± 11.8
Change from BL at Post-Surgery2.2 ± 12.03.5 ± 11.44.2 ± 11.33.4 ± 11.4
Change from BL at Post-BL Minimum-4.2 ± 9.2-7.4 ± 9.9-14.4 ± 10.7-8.3 ± 10.4
Change from BL at Post-BL Maximum9.5 ± 7.26.7 ± 11.14.8 ± 10.06.9 ± 10.1
SecondaryChange From Baseline in Systolic Blood Pressure

Systolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

Time frame:
Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Reported as:
Mean · millimetres of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure
millimetres of mercury (mmHg)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Baseline (BL) - Value at Visit135.4 ± 18.6128.0 ± 14.2129.4 ± 14.7130.0 ± 15.5
Change from BL at Day 8-1.1 ± 12.32.9 ± 14.0-7.9 ± 14.3-0.3 ± 14.2
Change from BL at Surgery-2.2 ± 15.75.7 ± 15.2-1.4 ± 17.32.2 ± 16.0
Change from BL at Post-Surgery-2.1 ± 14.61.0 ± 13.2-3.2 ± 15.3-0.7 ± 13.9
Change from BL at Post-BL Minimum-9.5 ± 12.0-5.5 ± 11.2-12.5 ± 14.6-8.0 ± 12.4
Change from BL at Post-BL Maximum5.9 ± 13.611.8 ± 13.43.2 ± 15.28.5 ± 14.2
SecondaryChange From Baseline in Diastolic Blood Pressure

Diastolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

Time frame:
Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Reported as:
Mean · millimetres of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure
millimetres of mercury (mmHg)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Baseline (BL) - Value at Visit78.4 ± 10.375.2 ± 10.776.9 ± 10.876.3 ± 10.6
Change from BL at Day 8-3.4 ± 7.3-0.5 ± 7.4-9.5 ± 10.3-3.1 ± 8.7
Change from BL at Surgery-3.2 ± 7.9-2.1 ± 12.5-8.3 ± 10.7-3.7 ± 11.2
Change from BL at Post-Surgery4.1 ± 8.00.1 ± 10.5-4.5 ± 9.80.0 ± 10.1
Change from BL at Post-BL Minimum-6.4 ± 6.6-6.2 ± 8.7-12.2 ± 8.5-7.6 ± 8.5
Change from BL at Post-BL Maximum5.6 ± 7.03.8 ± 10.8-2.8 ± 9.22.7 ± 10.1
SecondaryChange From Baseline in Body Temperature

Body temperature was measured according to institutional practice. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.

Time frame:
Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Reported as:
Mean · degrees Celsius (C)
Change From Baseline in Body Temperature
degrees Celsius (C)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Baseline (BL) - Value at Visit36.36 ± 0.4836.41 ± 0.3836.25 ± 0.2436.36 ± 0.38
Change from BL at Day 8-0.03 ± 0.41-0.06 ± 0.51-0.09 ± 0.43-0.06 ± 0.47
Change from BL at Surgery0.14 ± 0.51-0.09 ± 0.46-0.18 ± 0.43-0.05 ± 0.47
Change from BL at Post-Surgery-0.03 ± 0.56-0.05 ± 0.39-0.11 ± 0.50-0.06 ± 0.45
Change from BL at Post-BL Minimum-0.20 ± 0.52-0.34 ± 0.44-0.39 ± 0.42-0.32 ± 0.45
Change from BL at Post-BL Maximum0.28 ± 0.420.15 ± 0.440.12 ± 0.320.17 ± 0.41
SecondaryPercentage of Participants With Laboratory Abnormalities in Hematology Tests During Treatment, Among Participants Without the Abnormality at Baseline

Laboratory parameters for hematology will be measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Baseline, Days 1, 8, and 15
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Abnormalities in Hematology Tests During Treatment, Among Participants Without the Abnormality at Baseline
Percentage of participantsGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Hematocrit - Low03.202.0
Hematocrit - High22.2004.3
Hemoglobin - Low10.0002.0
Hemoglobin - High03.102.0
Lymphocytes, Absolute Count (Abs) - Low03.102.0
Lymphocytes, Abs - High03.212.54.1
Neutrophils, Total, Abs - Low03.202.0
Erythrocytes - Low22.26.708.5
Total Leukocyte Count - Low03.102.0
SecondaryPercentage of Participants With Laboratory Abnormalities in Blood Chemistry and Coagulation Tests During Treatment, Among Participants Without the Abnormality at Baseline

Laboratory parameters for blood chemistry and coagulation were measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase

Time frame:
Baseline, Days 1, 8, and 15
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Abnormalities in Blood Chemistry and Coagulation Tests During Treatment, Among Participants Without the Abnormality at Baseline
Percentage of participantsGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Albumin - Low03.302.1
Albumin - High03.302.1
Alkaline Phosphatase - High03.402.3
SGPT/ALT - High06.714.36.5
SGOT/AST - High03.114.34.2
Bicarbonate HCO3 - Low03.102.0
Bicarbonate HCO3 - High16.79.540.015.6
Blood Urea Nitrogen - High10.03.104.1
Calcium - High03.102.0
Carbon Dioxide - High33.325.0025.0
Chloride - Low10.03.212.56.1
Chloride - High09.406.3
Creatinine - High03.102.0
Direct Bilirubin - Low10.0002.4
Direct Bilirubin - High11.13.404.3
Glucose, Fasting - High031.3019.2
Glucose, Fasting Unknown - High33.321.433.325.0
Magnesium - High0012.52.0
Phosphorus - Low10.0002.0
Phosphorus - High03.202.0
Potassium - High03.102.0
Sodium - Low03.102.0
Bilirubin - High06.704.2
Protein, Total - Low03.302.2
Protein, Total - High03.202.0
Prothrombin Time - High03.001.6
International Normalized Ratio - High02.601.4
Activated Partial Thromboplastin Time - Low13.316.211.814.5
SecondaryPercentage of Participants With Abnormal Electrocardiogram Parameters During Treatment

Electrocardiogram (ECG) recordings were performed after the participant had been resting in a supine position for at least 10 minutes. ECG parameters included heart rate, PR and QRS durations, and QT and QTcF intervals. Per the protocol, ECG readings post-treatment were limited to those for whom it was clinically indicated. Any of the ECG parameters that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). An ECG test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Baseline, Days 1, 8, and 15
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormal Electrocardiogram Parameters During Treatment
Percentage of participantsGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety (ECG): Giredestrant (10, 30, or 100 mg)
PR Duration - Low12.5005.3
PR Duration - High0025.05.3
SecondaryPlasma Concentration of Giredestrant at Steady State by Dose Level

Plasma samples were obtained on the day of surgery (Day 15), or prior to biopsy on Day 14.

Time frame:
Predose on day of surgery (Day 15), or prior to biopsy (Day 14)
Reported as:
Geometric mean · nanograms per millilitre (ng/mL)
Plasma Concentration of Giredestrant at Steady State by Dose Level
nanograms per millilitre (ng/mL)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mg
Plasma Concentration of Giredestrant at Steady State by Dose Level58.8 ± 58.1130 ± 59.1441 ± 71.2

Adverse events

Collected over From Baseline to Day 43. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Giredestrant 10 mg0/17 (0%)1/17 (5.9%)12/17 (70.6%)
Giredestrant 30 mg0/40 (0%)2/40 (5%)21/40 (52.5%)
Giredestrant 100 mg0/17 (0%)1/17 (5.9%)14/17 (82.4%)
All Participants, Safety: Giredestrant (10, 30, or 100 mg)0/74 (0%)4/74 (5.4%)47/74 (63.5%)
Most frequent serious events
Most frequent serious events
EventGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
Breast abscessInfections and infestations1/170/400/171/74
DizzinessNervous system disorders0/170/401/171/74
MastitisInfections and infestations0/171/400/171/74
Breast haematomaReproductive system and breast disorders0/171/400/171/74
Most frequent other events
Showing 10 of 41
Most frequent other events
EventGiredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgAll Participants, Safety: Giredestrant (10, 30, or 100 mg)
FatigueGeneral disorders2/171/405/178/74
NauseaGastrointestinal disorders3/175/401/179/74
Procedural painInjury, poisoning and procedural complications2/171/403/176/74
PhotopsiaEye disorders0/170/402/172/74
Vision blurredEye disorders0/170/402/172/74
Skin infectionInfections and infestations2/170/400/172/74
SeromaInjury, poisoning and procedural complications2/171/402/175/74
Hot flushVascular disorders2/173/401/176/74
DizzinessNervous system disorders1/174/401/176/74
DyspepsiaGastrointestinal disorders0/173/400/173/74

Baseline characteristics

This is the Intent-to-Treat (ITT) Population, which includes all participants enrolled in the study regardless of whether they received any study drug.

Age, Continuous
Age, Continuous(Years)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Mean63.4 ± 8.964.1 ± 9.464.1 ± 7.763.9 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Female17401875
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Hispanic or Latino0404
Not Hispanic or Latino419629
Unknown or Not Reported13171242
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Asian0011
Black or African American0101
White16381771
Multiple1001
Unknown0101
Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline
Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
ECOG Performance Status of 017361770
ECOG Performance Status of 10404
Initial Staging of Breast Cancer (Breast Cancer History)
Initial Staging of Breast Cancer (Breast Cancer History)(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Stage I9191038
Stage II821736
Stage III0011
Tumor Grade (Breast Cancer History)
Tumor Grade (Breast Cancer History)(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Grade 1613423
Grade 29231244
Grade 32428
Nodal Status (Breast Cancer History)
Nodal Status (Breast Cancer History)(Participants)Giredestrant 10 mgGiredestrant 30 mgGiredestrant 100 mgTotal
Negative14371768
Positive2316
Missing1001
08

Study locations

15 sites
  • University of Colorado
    Aurora, Colorado 80045-2517, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Sunshine Hospital
    St Albans, Victoria 3021, Australia
  • Clinique Edith Cavell; Pharmacie
    Auderghem, 1160, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • Clinique Sainte-Elisabeth; Oncologie
    Namur, 5000, Belgium
  • Onkologikoa - Instituto Oncológico de Donostia
    San Sebastian, Guipuzcoa 20014, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Ruber Internacional;Servicio de Oncologia
    Madrid, 28034, Spain
  • HM Sanchinarro ? CIOCC
    Madrid, 28050, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Barts Health NHS Trust; William Harvey Heart Centre, QMUL School of Medicine & Dentistry
    London, EC1M 6BQ, United Kingdom
  • Royal Cornwall Hospital
    Truro, TR1 3LQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in May 2021, 21 months.

Results were first posted in Mar 2023, 1 year 9 months after primary completion.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 21 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
Apr 16, 2019
StartActual
Jul 26, 2019
Primary completionActual
May 25, 2021
CompletionActual
May 25, 2021
Results first posted
Mar 10, 2023
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03916744
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Jul 26, 2019
Primary completion
May 25, 2021
Completion
May 25, 2021
Results posted
Mar 10, 2023
Last update
Mar 10, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion